The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Vitamin D insufficiency and risk of paclitaxel-induced peripheral neuropathy.
 
Theodore Salvatore Jennaro
No Relationships to Disclose
 
Ellen M. Lavoie Smith
Consulting or Advisory Role - Disarm Therapeutics; Mundipharma Research
Research Funding - NIH/NCI (Inst)
 
Kiran Vangipuram
No Relationships to Disclose
 
Kelley M. Kidwell
Honoraria - Mallinckrodt
 
Monika Leigh Burness
No Relationships to Disclose
 
Jennifer J. Griggs
No Relationships to Disclose
 
Catherine H. Van Poznak
Research Funding - Bayer (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion; OncImmune
Consulting or Advisory Role - Agendia; Cellworks; Cepheid; CVS Caremark; Freenome
Research Funding - AstraZeneca (Inst); Lilly (Inst); Menarini Silicon Biosystems (Inst); Merrimack (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
Travel, Accommodations, Expenses - Menarini Silicon Biosystems
Other Relationship - Menarini
 
Norah Lynn Henry
Research Funding - Abbvie (Inst); H3 Biomedicine (Inst); Innocrin Pharma (Inst); Pfizer (Inst)
 
Daniel Louis Hertz
Other Relationship - Saladax Biomedical